Skip Navigation


Rheumatology Advance Access originally published online on April 9, 2009
Rheumatology 2009 48(6):597-598; doi:10.1093/rheumatology/kep060
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
48/6/597    most recent
kep060v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Dervieux, T.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Dervieux, T.
Related Collections
Right arrow Pharmacology
Right arrow Rheumatoid Arthritis
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2009. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For Permissions, please email: journals.permissions@oxfordjournals.org

EDITORIALS

Methotrexate pharmacogenomics in rheumatoid arthritis: introducing false-positive report probability

Thierry Dervieux1

1Cypress Bioscience, San Diego, CA, USA

Correspondence to: Thierry Dervieux, Cypress Bioscience, 9393 Towne Center Drive, San Diego, CA 92121, USA. E-mail: tdervieux@cypressbio.com

The first 150 words of the full text of this article appear below.

In this issue of the Journal, Lee and associates [1] investigated the contribution of candidate polymorphisms in folate and purine pathways to disease activity in RA patients treated with low-dose MTX therapy. This cross-sectional study analysis in patients enrolled in the BRASS (Brigham and Women's Hospital Rheumatoid Arthritis Sequential Study) cohort sought to replicate the earlier findings from our group [2–4] as well as those from Leiden University [5,6] among others. The results clearly illustrate the challenges and difficulties we face when validating associations between low-penetrance genetic polymorphisms and complex phenotypes such as drug response. In particular, the authors establish that the minor allele of rs4673993 in 5-aminoimidazole-4-carboxamide ribonucleotide (AICAR) transformylase (ATIC, in proxy with a C347G non-synonymous SNP encoding a threonine-to-serine substitution at position 116) is associated with improved clinical status, a finding consistent with the results observed in our . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Rheumatology (Oxford)Home page
T. Dervieux
Comment on: Methotrexate pharmacogenomics in rheumatoid arthritis: introducing false positive report probability: reply
Rheumatology, December 1, 2009; 48(12): 1620 - 1620.
[Full Text] [PDF]

Home page
 Rheumatology (Oxford)Home page
L. Beretta
Comment on: Methotrexate pharmacogenomics in rheumatoid arthritis: introducing false positive report probability
Rheumatology, December 1, 2009; 48(12): 1619 - 1620.
[Full Text] [PDF]